Janssen’s Remicade Biosimilar Infringement Case Against Samsung Bioepis Dismissed

Drug Industry Daily
Janssen Biotech and Samsung Bioepis jointly requested that Janssen’s patent infringement case be dismissed following the Supreme Court’s ruling earlier this year on the biosimilar approval process. The New Jersey federal court agreed to the motion last week.

To View This Article:


Subscribe To Drug Industry Daily